On this page
- What has been trialled
- The reviews, and what they contain
- Why Crohn’s and colitis are not interchangeable
- The refractory-patient problem
- How it would be given
- Measuring whether it worked
- What would have to happen for this to change
- Risks
- Questions worth asking
- Frequently asked questions
- Requesting a medical evaluation
Ulcerative colitis is usually studied under the wider heading of inflammatory bowel disease, alongside Crohn’s, and it comes off worse in the split. Stem cell therapy for ulcerative colitis has early trial activity and pooled reviews behind it, but no established benefit. Phase III studies in Crohn’s fistulas concern a different complication and have conflicting findings.
What has been trialled
An allogeneic marrow-derived product has been studied in medically refractory ulcerative colitis — A phase IB/IIA study of remestemcel-L, an allogeneic bone marrow-derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: an interim analysis.
Phase IB/IIA means early: primarily about safety and dose, in small numbers, and reported as an interim analysis rather than a completed trial.
That is a legitimate stage of research. It is not a basis for offering treatment commercially, and the distance between the two is the point of grading pages at all — what the evidence levels mean.
The reviews, and what they contain
A systematic review and meta-analysis covers inflammatory bowel disease as a whole — Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
A colitis-specific review pooled both clinical and experimental work — Mesenchymal stem cells for the treatment of ulcerative colitis: a systematic review and meta-analysis of experimental and clinical studies.
That phrase — experimental and clinical — is doing a great deal of work. Combining animal model results with human studies in one analysis inflates the apparent evidence base, and readers who see only the headline will not know how much of it came from mice.
Why Crohn’s and colitis are not interchangeable
They are grouped together clinically and share treatments, but they differ in where and how they affect the bowel. Crohn’s can involve any part of the gut in patches and through the full thickness of the wall. Ulcerative colitis affects the colon continuously and superficially.
Perianal fistula trials in Crohn’s disease address a specific complication. Their findings, including the unsuccessful confirmatory trial, cannot establish that the same approach works for ulcerative colitis.
Anyone citing the Crohn’s fistula trials as evidence for treating colitis is citing evidence about a complication your disease does not cause. See Crohn’s disease for what those trials actually covered.
The refractory-patient problem
Trials in this area recruit patients who have failed established treatment. That is where new treatments belong, and it also means results describe a population that has already exhausted the alternatives.
Ulcerative colitis has good established treatment: aminosalicylates, steroids for flares, immunomodulators, and several classes of biologic and small-molecule drug with large randomised trials behind them.
Colectomy, while a major operation, is also curative for the colonic disease in a way that no drug is. That option changes the calculation in colitis in a way it does not in Crohn’s.
How it would be given
Intravenous infusion of allogeneic cells is the route used in the trials, rather than local injection — there is no fistula tract to target.
Some research has explored delivery directly to the bowel lining by endoscopy. That remains investigational.
Mesenchymal stem cell therapy covers cell sources, dosing and what is known about where infused cells go.
Measuring whether it worked
Symptom improvement in colitis is unreliable on its own. Disease activity fluctuates, and patients feel better for many reasons.
Serious trials use endoscopic assessment — looking at the bowel lining — alongside symptom scores, and increasingly histological healing from biopsies.
If a clinic proposes treatment without any plan for endoscopic follow-up, there is no way to know whether anything changed. That is worth asking about before rather than after.
What would have to happen for this to change
A completed phase III trial in ulcerative colitis specifically, with endoscopic remission as the primary endpoint and a placebo arm, reported in full rather than as an interim analysis.
Nothing of that description has been published. Until it is, treatment offered commercially for this condition is being offered ahead of its evidence, whatever the accompanying material says.
That is a statement about timing rather than about plausibility. Inflammatory bowel disease is a reasonable target, the mechanism is coherent, and the early work is real early work. The gap is between where the research has reached and where the marketing has already gone.
Someone considering enrolling in a trial is in a different position from someone considering paying for treatment, and the distinction is worth keeping clearly in mind.
Risks
Infection risk in patients on background immunosuppression, which describes most people in this group.
Infusion reactions and transient fever, as elsewhere in this field.
Delay is the risk that is easy to overlook. Uncontrolled colitis carries its own hazards, and time spent on an unproven treatment while inflammation continues is not neutral. Adverse events covers documented harms.
Long-standing extensive colitis also carries a raised risk of bowel cancer, which is why surveillance colonoscopy is part of standard care. Any treatment plan that takes someone out of that surveillance pathway costs them something real.
Questions worth asking
- Have I completed established treatment under a gastroenterologist?
- Which ulcerative colitis trial does this protocol follow, and what stage had it reached?
- How will response be assessed — symptoms alone, or endoscopy?
- What happens to my current medication during and after?
The autoimmune overview sets out how this group compares, and the limits of current evidence covers what remains unknown.
Frequently asked questions
Is the evidence here as good as for Crohn’s?
No. The Crohn’s trials concern perianal fistulas, and their phase III findings conflict. They do not establish benefit for ulcerative colitis.
What does phase IB/IIA mean?
Early research, mainly about safety and dose, in small numbers. The colitis study was also reported as an interim analysis rather than a completed trial.
The meta-analysis sounds positive. Why is this graded early?
Because one of the reviews pools animal experiments with human studies. That combination makes the evidence base look larger than the human data alone.
Should I try this before biologics?
Nothing published supports that. Trials recruited patients who had already failed established treatment.
How would anyone know if it worked?
Endoscopy. Symptom scores alone are unreliable in a condition that fluctuates, so ask what follow-up assessment is planned.
Is surgery still an option afterwards?
Yes, and for colitis, removing the colon resolves the colonic disease in a way drugs do not. That changes the trade-off here.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.